CONSTANT LEVERAGE LONG - ELI LILLY & CO | Market Closed - Euronext Paris 17:30:01 15/05/2024 BST | ||
| 7.71 EUR | +24.86% |
|
| Current month | -11.04% | ||
| 1 month | -8.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 7.71 | +24.86% |
| 14/05/24 | 6.175 | +0.41% |
| 13/05/24 | 6.15 | -10.35% |
| 10/05/24 | 6.86 | -9.20% |
| 09/05/24 | 7.555 | -2.95% |
Real-time Euronext Paris
Last update May 15, 2024 at 05:30 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| XL5NB | |
| ISIN | NLBNPNL2OS26 |
| Date issued | 13/03/2024 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.02 € |
|---|---|
| Lowest since issue | 5.06 € |
| Spread | 0.16 € |
| Spread % | 2.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Certificates
- XL5NB Certificat
